Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Developmen... (diluted net loss per share ...)

Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs

Date:8/19/2007

diluted

net loss per share $(0.21) $(0.11) $(0.45) $(0.27)

Shares used to calculate

basic and diluted net

loss per share 39,191 28,817 39,186 28,555

Balance Sheets June 30, December 31,

(in thousands) 2007 2006

Assets:

Cash, cash equivalents, and

marketable securities $82,153 $100,393

Other current assets 4,340 5,049

Total current assets 86,493 105,442

Property and equipment, net 13,031 13,500

Other assets 5,899 6,307

Total assets $105,423 $125,249

Liabilities and stockholders' equity:

Current liabilities $5,500 $8,153

Long-term obligations 2,735 2,973

Stockholders' equity 97,188 114,123

Total liabilities and stockholders' equity $105,423 $125,249

Contacts: Alan R. Engbring Jill M. Church

Executive Director, Vice President and

Investor Relations Chief Financial Officer

(858) 646-1127

SOURCE Vical

Post Your Comments:

Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Developmen...(diluted net loss per share ...),Health